UPDATE: JPMorgan Upgrades Protagonist Therapeutics (PTGX) to Overweight
Tweet Send to a Friend
(Updated - October 12, 2021 4:11 AM EDT)
JPMorgan analyst Anupam Rama upgraded Protagonist Therapeutics (NASDAQ: PTGX) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Anupam Rama upgraded Protagonist Therapeutics (NASDAQ: PTGX) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
